A006620 Stock Overview
DongKoo Bio & Pharma Co., Ltd. manufactures and sells pharmaceuticals in South Korea.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 4/6 |
Dividends | 2/6 |
DongKoo Bio & Pharma Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩6,860.00 |
52 Week High | ₩7,110.00 |
52 Week Low | ₩4,615.00 |
Beta | 0.85 |
1 Month Change | 11.54% |
3 Month Change | 15.68% |
1 Year Change | 13.95% |
3 Year Change | -30.43% |
5 Year Change | 1.38% |
Change since IPO | -46.55% |
Recent News & Updates
Shareholder Returns
A006620 | KR Pharmaceuticals | KR Market | |
---|---|---|---|
7D | 5.1% | 3.9% | 0.5% |
1Y | 14.0% | 8.3% | 4.7% |
Return vs Industry: A006620 exceeded the KR Pharmaceuticals industry which returned 8.3% over the past year.
Return vs Market: A006620 exceeded the KR Market which returned 4.7% over the past year.
Price Volatility
A006620 volatility | |
---|---|
A006620 Average Weekly Movement | 5.8% |
Pharmaceuticals Industry Average Movement | 4.6% |
Market Average Movement | 5.3% |
10% most volatile stocks in KR Market | 11.8% |
10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A006620 has not had significant price volatility in the past 3 months.
Volatility Over Time: A006620's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1970 | 355 | Cho Yong-Jun | www.dongkoo.com |
DongKoo Bio & Pharma Co., Ltd. manufactures and sells pharmaceuticals in South Korea. The company provides prescription drugs, such as antihistamines, dermatological oral medications, ophthalmic solutions, skeletal muscle relaxants, anti-inflammatory enzymes, antivirals, antibacterial agents, and for the treatment of allergies, liver diseases, mental illnesses, obesity, brain nervous, and endocrine systems; over-the-counter medicines, such as dermatological external preparations, antifungal agents, active probiotic intestinal supplements, antipyretic anti-inflammatory analgesics, and for the treatment of the respiratory, digestive, genitourinary, and circulatory systems; and quasi-drugs.
DongKoo Bio & Pharma Co., Ltd. Fundamentals Summary
A006620 fundamental statistics | |
---|---|
Market cap | ₩189.39b |
Earnings (TTM) | ₩11.81b |
Revenue (TTM) | ₩215.69b |
16.0x
P/E Ratio0.9x
P/S RatioIs A006620 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A006620 income statement (TTM) | |
---|---|
Revenue | ₩215.69b |
Cost of Revenue | ₩83.61b |
Gross Profit | ₩132.08b |
Other Expenses | ₩120.26b |
Earnings | ₩11.81b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 427.83 |
Gross Margin | 61.24% |
Net Profit Margin | 5.48% |
Debt/Equity Ratio | 38.0% |
How did A006620 perform over the long term?
See historical performance and comparison